
Validea's guru fundamental report assigns UnitedHealth Group (UNH), a large-cap health insurer, a 77% rating using its Martin Zweig-inspired Growth Investor model, placing it just below the 80% threshold for 'some interest.' While UNH passed criteria for P/E ratio, sales growth, current quarter earnings, and long-term EPS growth, it notably failed tests related to consistent and accelerating earnings growth over several quarters and in relation to revenue growth. This indicates that while UNH exhibits several growth characteristics and reasonable valuation, it shows some inconsistencies in the persistent and accelerating earnings growth prioritized by the Zweig strategy.
UnitedHealth Group (UNH) receives a 77% rating from Validea's Growth Investor model, which is based on the strategy of Martin Zweig. This score is just shy of the 80% threshold that typically signals strategic interest. The analysis reveals a mixed fundamental picture: UNH demonstrates strength in several key areas, passing tests for its P/E ratio, overall sales growth rate, current quarter earnings performance, earnings persistence, and long-term EPS growth. Favorable insider transaction data further supports a stable outlook. However, the model flags critical weaknesses regarding the quality and consistency of its growth. Specifically, UNH fails on criteria measuring sustained earnings growth over the past several quarters and its current EPS growth rate's ability to exceed its historical trend. Furthermore, a flagged imbalance between revenue and EPS growth suggests potential margin pressure or inconsistencies that detract from the ideal high-growth profile sought by the Zweig strategy.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
Neutral
Sentiment Score
0.15
Ticker Sentiment